The Zydus Lifesciences stock snapped its three-day losing streak to climb 2 per cent higher in Wednesday’s trade after the drugmaker announced the launch of a critical bone health therapy in India and a strategic licensing pact for the North American market.

Shares of Zydus Lifesciences gained as much as 1.8 per cent at Rs 937 in Wednesday’s trade, from a previous close of Rs 919.90 on the BSE. While the stock had been declining for the past three sessions, it managed to snap its losing run today. Despite this uptick, the stock remains down over 4 per cent in 2025 so far. Advertisement

In a filing to exchanges on December 10, the Ahmedabad-headquartered firm announced the launch of 'Zyrifa', a biosimilar of Denosumab, aimed at protecting bone health in cancer patients. Priced at an MRP

See Full Page